Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma

Autor: S. Canova, G.L. Ceresoli, F. Grosso, P.A. Zucali, F. Gelsomino, G. Pasello, M. Mencoboni, E. Rulli, F. Galli, I. De Simone, L. Carlucci, A. De Angelis, M. Belletti, M. Bonomi, A. D’Aveni, M. Perrino, F. Bono, D.L. Cortinovis, D. Cortinovis, F. Colonese, M.I. Abbate, L. Sala, E. Sala, M. Perez Gila, F. Pagni, F. Ugo, F. De Vincenzo, A. Santoro, A. Ardizzoni, S. Frega, M. D’Incalci, D. Poli, V. Torri

Background: Malignant pleural mesothelioma (MPM) is a cancer with a high mortality rate and few therapeutic options. After platinum–pemetrexed combination, no further promising drug seems to be effective. Immune checkpoint inhibitors may have some

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bad29d6a2db87ae9ecc56329d3b9dee
https://hdl.handle.net/11577/3464949

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Role of FDG PET/CT in the prognostic stratification and response assessment of castration-resistant prostate cancer treated with radium-223 dichloride

Autor: M. Donegani 1, S. Capitanio 2, M. Vitti 1, G. Fornarini 2, A. Miceli 1, E. Zanardi 1, M. Mencoboni 3, C. Marini 2, 4, F. Boccardo 1, G. Sambuceti 1, 2, S. Morbelli 1, M. Bauckneht 2

Publikováno v: European journal of nuclear medicine and molecular imaging (Internet) 46 (2019): S627–S628.
info:cnr-pdr/source/autori:M. Donegani 1, S. Capitanio 2, M. Vitti 1, G. Fornarini 2, A. Miceli 1, E. Zanardi 1, M. Mencoboni 3, C. Marini 2,4, F. Boccardo 1, G. Sambuceti 1,2, S. Morbelli 1,2, M. Bauckneht 2/titolo:Role of FDG PET%2FCT in the prognostic stratification and response assessment of castration-resistant prostate cancer treated with radium-223 dichloride/doi:/rivista:European journal of nuclear medicine and molecular imaging (Internet)/anno:2019/pagina_da:S627/pagina_a:S628/intervallo_pagine:S627–S628/volume:46

Aim/Introduction: Radium-223 dichloride has emerged as the only bone-directed treatment option demonstrating an improvement in overall survival (OS) in metastatic castrate resistant prostate cancer (mCRPC). However, there is an urgent need for the id

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::105a65650f51158fb46eab174e626015
http://www.cnr.it/prodotto/i/409534

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.